Scancell Holdings Plc Scancell to present at the Calculus Investor Forum
16 February 2018 - 10:30PM
RNS Non-Regulatory
TIDMSCLP
Scancell Holdings Plc
16 February 2018
16 February 2018
Scancell Holdings Plc
("Scancell" or the "Company")
Scancell to present at the Calculus Investor Forum
Scancell Holdings plc, ('Scancell' or the 'Company') the
developer of novel immunotherapies for the treatment of cancer,
announces that Cliff Holloway, Chief Executive Officer and Lindy
Durrant, Chief Scientific Officer, have been invited to present an
overview of the Company alongside recognised experts in the fields
of melanoma, lung cancer and the development of innovative
immunotherapies, at the Calculus Investor Forum in London on Friday
16 February 2018 at 12.15pm GMT.
A PDF of the presentation will be available on the investors
section of the Scancell website at the same time and a recording
will be available thereafter. There will be no material information
presented that is not already in the public domain.
For Further Information:
Scancell
Dr John Chiplin, Chairman
Dr Cliff Holloway, Scancell Holdings
CEO Plc +1 858 361 6288
Freddy Crossley (Corporate
Finance)
Tom Salvesen (Corporate Panmure Gordon +44 (0) 20 7886
Broking) & Co 2500
+44 (0) 20 3727
Mo Noonan/Simon Conway FTI Consulting 1000
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its ImmunoBody(R) and Moditope(R) technology
platforms.
Scancell's first ImmunoBody(R), SCIB1 is being developed for the
treatment of melanoma. Data from the Phase 1/2 clinical trial
demonstrate that SCIB1, when used as monotherapy, has a marked
effect on tumour load, produces a melanoma-specific immune response
and highly encouraging survival trend without serious side effects.
In patients with resected disease there is increasing evidence to
suggest that SCIB1 may delay or prevent disease recurrence.
Scancell's ImmunoBody(R) vaccines target dendritic cells and
stimulate both parts of the cellular immune system: the helper cell
system where inflammation is stimulated at the tumour site and the
cytotoxic T-lymphocyte or CTL response where immune system cells
are primed to recognise and kill specific cells.
Pre-clinical data on a combination of SCIB1 or SCIB2 and
checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune
checkpoint pathways) have shown enhanced tumour destruction and
significantly longer survival times than when either treatment was
used alone.
Scancell has also identified and patented a series of modified
epitopes that stimulate the production of killer CD4+ T cells that
destroy tumours with minimal toxicity. The Directors believe that
the Moditope(R) platform could play a major role in the development
of safe and effective cancer immunotherapies in the future.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRASFWFAIFASEEE
(END) Dow Jones Newswires
February 16, 2018 06:30 ET (11:30 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2024 to May 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From May 2023 to May 2024